Stock Track | Arvinas Soars 5.17% in Pre-Market on Positive Quarterly Results and Promising Drug Updates

Stock Track

02-11

Arvinas Holding Company LLC saw its stock surge 5.17% in pre-market trading on Tuesday, outperforming the broader market.

The biopharmaceutical company's impressive gains were driven by its better-than-expected fourth quarter 2024 earnings report and positive updates on its drug pipeline. Arvinas reported a narrower net loss of $0.63 per share, beating analyst estimates of a $0.96 loss. The company also announced that its cash reserves of $1.04 billion as of December 31, 2024 would be sufficient to fund operations until 2027.

Furthermore, Arvinas provided promising updates on its collaboration with Pfizer, including plans to announce topline data for its oral PROTAC degrader vepdegestrant in the near future. The company's strong cash position and promising drug candidates fueled investor optimism, leading to the significant pre-market rally.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1102531516"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1102531516\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1102531516?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-11 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102531516","market":"hk","top_or_hot":-1,"title":"Stock Track | Arvinas Soars 5.17% in Pre-Market on Positive Quarterly Results and Promising Drug Updates","media":"Stock Track","content":"<p>Arvinas Holding Company LLC saw its stock surge 5.17% in pre-market trading on Tuesday, outperforming the broader market.</p>\n\n<p>The biopharmaceutical company's impressive gains were driven by its better-than-expected fourth quarter 2024 earnings report and positive updates on its drug pipeline. Arvinas reported a narrower net loss of $0.63 per share, beating analyst estimates of a $0.96 loss. The company also announced that its cash reserves of $1.04 billion as of December 31, 2024 would be sufficient to fund operations until 2027.</p>\n\n<p>Furthermore, Arvinas provided promising updates on its collaboration with Pfizer, including plans to announce topline data for its oral PROTAC degrader vepdegestrant in the near future. The company's strong cash position and promising drug candidates fueled investor optimism, leading to the significant pre-market rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arvinas Soars 5.17% in Pre-Market on Positive Quarterly Results and Promising Drug Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arvinas Soars 5.17% in Pre-Market on Positive Quarterly Results and Promising Drug Updates\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-11 21:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Arvinas Holding Company LLC saw its stock surge 5.17% in pre-market trading on Tuesday, outperforming the broader market.</p>\n\n<p>The biopharmaceutical company's impressive gains were driven by its better-than-expected fourth quarter 2024 earnings report and positive updates on its drug pipeline. Arvinas reported a narrower net loss of $0.63 per share, beating analyst estimates of a $0.96 loss. The company also announced that its cash reserves of $1.04 billion as of December 31, 2024 would be sufficient to fund operations until 2027.</p>\n\n<p>Furthermore, Arvinas provided promising updates on its collaboration with Pfizer, including plans to announce topline data for its oral PROTAC degrader vepdegestrant in the near future. The company's strong cash position and promising drug candidates fueled investor optimism, leading to the significant pre-market rally.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARVN","symbol_name":"Arvinas Holding Company LLC","start_time":0,"source_url":"","article_id":"1102531516","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102531516","pubTimestamp":1739279028,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arvinas Holding Company LLC saw its stock surge 5.17% in pre-market trading on Tuesday, outperforming the broader market.The biopharmaceutical company's impressive gains were driven by its better-than-expected fourth quarter 2024 earnings report and positive updates on its drug pipeline. Arvinas reported a narrower net loss of $0.63 per share, beating analyst estimates of a $0.96 loss. The company also announced that its cash reserves of $1.04 billion as of December 31, 2024 would be sufficient ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARVN":"Arvinas Holding Company LLC"},"translate_title":"股票赛道Arvinas盘前飙升5.17%，因积极的季度业绩和有希望的药物更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARVN":1},"content_text":"Arvinas Holding Company LLC saw its stock surge 5.17% in pre-market trading on Tuesday, outperforming the broader market.\nThe biopharmaceutical company's impressive gains were driven by its better-than-expected fourth quarter 2024 earnings report and positive updates on its drug pipeline. Arvinas reported a narrower net loss of $0.63 per share, beating analyst estimates of a $0.96 loss. The company also announced that its cash reserves of $1.04 billion as of December 31, 2024 would be sufficient to fund operations until 2027.\nFurthermore, Arvinas provided promising updates on its collaboration with Pfizer, including plans to announce topline data for its oral PROTAC degrader vepdegestrant in the near future. The company's strong cash position and promising drug candidates fueled investor optimism, leading to the significant pre-market rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}